Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study was an interventional non-randomized controlled study and was divided into a Sitagliptin monotherapy (100 mg Qd) group and a Sitagliptin (100mg Qd)+Beidougen capsule (60mg Tid) combination treatment group for one week.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Chao Yang Hospital
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Patients aged 18-65 years with a first diagnosis of type 2 diabetes

• Diagnostic criteria HbA1c ≥ 7%

Exclusion Criteria:

• The positive of diabetes antibodies

• Anti-diabetic drugs therapy before participation

• Pancreatitis

• Coronary artery disease

• Liver function impairment

• Renal function impairment

• History of intestinal surgery

• Chronic hypoxic diseases (emphysema and cor pulmonale)

• Infectious disease

• Hematological disease

• Systemic inflammatory disease

• Cancer

• Pregnant

• Ingesting agents known to influence glucose or lipid metabolism

• Any antibiotics or probiotics in the past three months prior to the study